Sugi Predict

Sugi Predict / Compounds / SCHEMBL22229983

SCHEMBL22229983

SCHEMBL22229983

CCc1cc(C(=O)O)cc2sc(Cl)nc12

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 3/20 0.40
▸ DAO P14920 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ CTRC Q99895 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TPMT P51580 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4D Q08499 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2652019 0.82 CYP2C19 (0.44) DAOALDH1A1HPGDNPC1RAB9A
SCHEMBL20554157 0.78 NR1H4 (0.39) NR1H4TPMT
SCHEMBL20554083 0.78 ALDH1A1 (0.51) NR1H4ALDH1A1TPMT
SCHEMBL6057547 0.77 SMN1; SMN2 (0.48) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL15464299 0.76 ALDH1A1 (0.39) ALDH1A1NPC1RAB9AKMT2A
SCHEMBL29388048 0.72 NPC1 (0.49) DAOALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7469260 0.69 ALDH1A1 (0.59) ALDH1A1HPGDCTRCRAB9ASMN1; SMN2
SCHEMBL20031235 0.69 RAB9A (0.41) NR1H4DAOALDH1A1HPGDNPC1
SCHEMBL1036069 0.68 KDM4E (0.62) ALDH1A1HPGDNPC1RAB9ASMN1; SMN2
SCHEMBL28548830 0.68 RAB9A (0.45) ALDH1A1HPGDNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3911640-B1 PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE ASTRAZENECA AB (SE) 2026-05-13 — — EP disclosed
US-12584120-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-03-24 — — US disclosed
US-12552807-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2026-02-17 — — US disclosed
CN-119112897-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2024-12-13 — — CN disclosed
CN-119119023-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2024-12-13 — — CN disclosed
CN-119119022-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2024-12-13 — — CN disclosed
EP-4470609-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2024-12-04 — — EP disclosed
CN-119060040-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2024-12-03 — — CN disclosed
EP-3911648-B1 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2024-10-23 — — EP disclosed
CN-113574055-B PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2024-07-23 — — CN disclosed
US-20220220122-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11248001-B2 PCSK9 inhibitors and methods of use thereof ASTRAZENECA AB (SE) 2022-02-15 — — US disclosed
EP-3911640-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 — — EP disclosed
EP-3911648-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF Astrazeneca AB (SE) 2021-11-24 — — EP disclosed
CN-113574055-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2021-10-29 — — CN disclosed
CN-113412258-A PCSK9 inhibitors and methods of use thereof 阿斯利康(瑞典)有限公司 2021-09-17 — — CN disclosed
US-20200291041-A1 PCSK9 Inhibitors and Methods of Use Thereof ASTRAZENECA AB (SE) 2020-09-17 — — US disclosed
US-20200231584-A1 PCSK9 Inhibitors and Methods of Use Thereof ASTRAZENECA AB (SE) 2020-07-23 — — US disclosed
WO-2020150473-A2 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 — — WO disclosed
WO-2020150474-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF DOGMA THERAPEUTICS, INC. (US) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11248001-B2 PCSK9 inhibitors and methods of use thereof PCSK9, PCSK7, PCSK6 NR1H4 112/4885DAO 3139/4885ALDH1A1 4217/4885
US-20200291041-A1 PCSK9 Inhibitors and Methods of Use Thereof PCSK9, PCSK7, PCSK6 NR1H4 289/4885DAO 2850/4885ALDH1A1 4495/4885
US-12552807-B2 PCSK9 inhibitors and methods of use thereof PCSK9, PCSK7, PCSK6 NR1H4 96/4885DAO 1253/4885ALDH1A1 4688/4885
US-12584120-B2 PCSK9 inhibitors and methods of use thereof PCSK9, LDLR, PCSK7 NR1H4 56/4885DAO 1156/4885ALDH1A1 4830/4885
US-20200231584-A1 PCSK9 Inhibitors and Methods of Use Thereof PCSK9, PCSK7, PCSK6 NR1H4 62/4885DAO 2293/4885ALDH1A1 4227/4885
US-20220220122-A1 PCSK9 INHIBITORS AND METHODS OF USE THEREOF PCSK9, PCSK7, PCSK6 NR1H4 289/4885DAO 2850/4885ALDH1A1 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.